Floatz logo

Monomethyl Fumarate

Glioblastoma, IDH-Wildtype

Northwestern UniversitySmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

9 Active assets in the Glioblastoma, IDH-Wildtype cohort.

Asset / SponsorPhaseRating
Nivolumab
Neonc Technologies, Inc.
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2B
Ipilimumab
Neonc Technologies, Inc.
Phase 2B
WP 1066
Northwestern University
Phase 2CCC
gi-102
Mayo Clinic
Phase 2CCC

View all 9 →

Same molecule, other indications

Monomethyl Fumarate is also rated in:

Blood Stem Cell Transplant FailureDormant
BBB
Indicative ·
76 / 100
View asset →
Fanconi AnemiaDormant
BBB
Indicative ·
74 / 100
View asset →
Refractory Anemia With Excess BlastsDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →